These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Neoadjuvant and adjuvant treatment of renal cell carcinoma. Thillai K; Allan S; Powles T; Rudman S; Chowdhury S Expert Rev Anticancer Ther; 2012 Jun; 12(6):765-76. PubMed ID: 22716493 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Repmann R; Goldschmidt AJ; Richter A Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332 [TBL] [Abstract][Full Text] [Related]
9. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957 [TBL] [Abstract][Full Text] [Related]
10. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Wood CG Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296 [TBL] [Abstract][Full Text] [Related]
11. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma? Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207 [TBL] [Abstract][Full Text] [Related]
12. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919 [TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology. Tobert CM; Uzzo RG; Wood CG; Lane BR Urol Oncol; 2013 Oct; 31(7):1316-20. PubMed ID: 22264501 [TBL] [Abstract][Full Text] [Related]
16. Advances in immune-based therapies of renal cell carcinoma. Lam JS; Belldegrun AS; Figlin RA Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335 [TBL] [Abstract][Full Text] [Related]
17. [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?]. Doehn C; Merseburger AS; Jocham D; Kuczyk MA Urologe A; 2007 Oct; 46(10):1371-2, 1374, 1376-8. PubMed ID: 17805507 [TBL] [Abstract][Full Text] [Related]
19. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Polcari AJ; Gorbonos A; Milner JE; Flanigan RC Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114 [TBL] [Abstract][Full Text] [Related]
20. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Karam JA; Wood CG Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]